Adam Kaufman, MD
Ophthalmology · Cincinnati, OHNPI 1609819085
Payments from drug & device makers
Across 232 payments — averaging $80.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$4K
- Alcon$4K
- Recordati_rare_diseases_inc.$3K
- Sight Sciences, Inc.$3K
- Haag-streit USA, Inc.$1K
- Biotissue Holdings Inc.$664
- plus $4K from 25 others
What the payments were for
- Speaking & faculty fees$7,99243%
- Travel & lodging$8515%
- Food & beverage$9,06749%
- Education$1881%
- Entertainment$4703%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 17 | $3,683 |
| Alcon | 65 | $3,650 |
| Recordati_rare_diseases_inc. | 1 | $3,092 |
| Sight Sciences, Inc. | 1 | $2,500 |
| Haag-streit USA, Inc. | 11 | $1,008 |
| Biotissue Holdings Inc. | 16 | $664 |
| Glaukos Corporation | 7 | $548 |
| Mallinckrodt Hospital Products Inc. | 12 | $486 |
| Johnson & Johnson Surgical Vision, Inc. | 13 | $439 |
| AbbVie(2 entities) | 15 | $342 |
| Sun Pharmaceutical Industries Inc. | 14 | $256 |
| Regeneron Healthcare Solutions, Inc. | 7 | $220 |
| Harrow Eye, LLC | 5 | $218 |
| Aerie Pharmaceuticals, Inc. | 10 | $199 |
| Dompe US, Inc. | 6 | $185 |
| Carl Zeiss Meditec USA, Inc. | 4 | $174 |
| Integra Lifesciences Corporation | 1 | $127 |
| Amgen | 1 | $121 |
| Mallinckrodt Enterprises LLC | 2 | $118 |
| Oyster Point Pharma, Inc. | 4 | $86 |
| Rayner Intraocular Lenses Limited | 2 | $78 |
| ANI Pharmaceuticals, Inc. | 2 | $69 |
| Novartis | 3 | $61 |
| Bausch & Lomb Americas Inc. | 3 | $61 |
| Astellas Pharma US Inc | 2 | $47 |
| Kala Pharmaceuticals, Inc. | 2 | $40 |
| Tarsus Pharmaceuticals, Inc. | 2 | $37 |
| Thea Pharma Inc. | 1 | $19 |
| Eyepoint US, Inc. | 1 | $16 |
| Immunogen, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS PC$3,224
- CRYSTALENS$3,224
- AKREOS AO$3,224
- ENVISTA$3,224
- TRULIGN TORIC$3,224
- OMNI(R) SURGICAL SYSTEM (US)$2,500
- SION SURGICAL INSTRUMENT$2,500
- Clareon$603
- Hydrus Microstent$411
- ReSTOR$247
- Photrexa$222
- Wavelight$150
- AcrySof IQ TORIC IOL$137
- CODMAN CERTAS$127
- CUSA CLARITY$127
- DURAGEN$127
- DURASEAL EXACT$127
- CODMAN HAKIM PRECISION VALVE$127
- TEPEZZA$121
- Wavelight Refractive Suite$120
How this compares
$18,568 in reported general payments places this provider in the 90th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 35 | $27,289 |
| CiloxanCiprofloxacin Hcl | 88 | $26,104 |
| Prednisolone Acetate | 543 | $19,903 |
| MoxifloxacinMoxifloxacin Hcl | 303 | $16,128 |
| Difluprednate | 43 | $15,182 |
| Alphagan PBrimonidine Tartrate | 42 | $13,031 |
| CequaCyclosporine | 14 | $12,259 |
| ValacyclovirValacyclovir Hcl | 178 | $9,857 |
| Valganciclovir Hcl | 12 | $9,520 |
| ZirganGanciclovir | 18 | $8,465 |
| Fluorometholone | 76 | $6,470 |
| Cyclosporine | 19 | $6,065 |
| RhopressaNetarsudil Mesylate | 12 | $5,629 |
| Ketorolac Tromethamine | 331 | $5,253 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $3,759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Alphagan P, Combigan | $342 | $44,07895 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $256 | $12,25914 claims |
| Bausch & Lomb Americas Inc.Zirgan | $61 | $8,46518 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $199 | $5,62912 claims |
| AlconSimbrinza | $3,650 | $2,39612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Cincinnati
- Daniel MillerCincinnati$2.3M
- Michael SnyderCincinnati$1.3M
- Christopher RiemannCincinnati$985K
- Robert SiskCincinnati$831K
- Anup KhatanaCincinnati$794K
- Robert OsherCincinnati$720K
- Haroon ChaudhryCincinnati$708K
- Christopher DevineCincinnati$623K
- Robert BenzaCincinnati$224K
- Linda GreffCincinnati$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.